• Cécile Ortholan, Alain Ramaioli, Didier Peiffert, Antoine Lusinchi, Pascale Romestaing, Laurent Chauveinc, Emmanuel Touboul, Karine Peignaux, Antoine Bruna, Guy de La Roche, Jean-Léon Lagrange, Christian Alzieu, and Jean Pierre Gerard.
• Department of Radiation Oncology, Centre Antoine Lacassagne, Nice, France. c.ortholan@wanadoo.fr
• Int. J. Radiat. Oncol. Biol. Phys. 2005 Jun 1; 62 (2): 479-85.

PurposeTo investigate the clinical history, management, and pattern of recurrence of very early-stage anal canal cancer in a French retrospective survey.MethodsThe study group consisted of 69 patients with Stage Tis and T1 anal canal carcinoma < or =1 cm treated between 1990 and 2000 (12 were in situ, 57 invasive, 66 Stage N0, and 3 Stage N1). The median patient age was 67 years (range, 27-83 years). Of the 69 patients, 66 received radiotherapy (RT) and 3 with in situ disease were treated by local excision alone without RT. Twenty-six patients underwent local excision before RT (12 with negative and 14 with positive surgical margins). Of the 66 patients who underwent RT, 8 underwent brachytherapy alone (median dose, 55 Gy), 38 underwent external beam RT (median dose, 45 Gy) plus a brachytherapy boost (median boost dose, 20 Gy), and 20 underwent external beam RT alone (median dose, 55 Gy).ResultsOf the 69 patients, 68 had initial local control. Of the 66 patients treated by RT, 6 developed local recurrence at a median interval of 50 months (range, 13-78 months). Four patients developed local failure outside the initial tumor bed. Of the 3 patients with Tis treated by excision alone, 1 developed local recurrence. No relation was found among prior excision, dose, and local failure. The 5-year overall survival, colostomy-free survival, and disease-free survival rate was 94%, 85%, and 89%, respectively. The rate of late complications (Grade 1-3) was 28% and was 14% for those who received doses <60 Gy and 37% for those who received doses of > or =60 Gy (p = 0.04).ConclusionMost recurrences occurred after a long disease-free interval after treatment and often outside the initial tumor site. These small anal cancers could be treated by RT using a small volume and moderate dose (40-50 Gy for subclinical lesions and 50-60 Gy for T1).

30 keywords...

hide…